We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
23andme Holding Co
21 own
8 watching
Current Price
$2.06
$-0.02
(-0.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
941.75M
52-Week High
6.31
52-Week Low
1.74
Average Volume
3.39M
Dividend Yield
--
P/E Ratio
--
Market Capitalization941.75M52-Week High6.3152-Week Low1.74Average Volume3.39MDividend Yield--P/E Ratio--What does the 23andme Holding Co do?
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Read More
News & Events about 23andme Holding Co.
Globe Newswire
2 months ago
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customersSOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today ...
Globe Newswire
3 months ago
92 percent of doctors in the U.S. say genetics is an important part of a patients complete health picture66 percent of doctors say genetic testing could help lead to better outcomes for their patients75 percent of people in the US said theyd be more likely to follow their doctors advice if they knew...
Globe Newswire
6 months ago
-14 percent of those surveyed say theyre stressed, compared to more than 47 percent in 2020-Under 20 percent of those surveyed said COVID-19 would interfere with their traditional holiday plans; down from 62 percent in 2020-However, most respondents still have some concern about their overall health...
Globe Newswire
7 months ago
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activitySOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human ...
Frequently Asked Questions
Frequently Asked Questions
What is 23andme Holding Co share price today?
Can Indians buy 23andme Holding Co shares?
How can I buy 23andme Holding Co shares from India?
Can Fractional shares of 23andme Holding Co be purchased?
What are the documents required to start investing in 23andme Holding Co stocks?
What is today’s traded volume of 23andme Holding Co?
What is today’s market capitalisation of 23andme Holding Co?
What is the 52-Week High and Low Range of 23andme Holding Co?
What percentage is 23andme Holding Co down from its 52-Week High?
What percentage is 23andme Holding Co up from its 52-Week Low?
Current Price
$2.06
$-0.02
(-0.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.